About: ACE inhibition and endothelial function: Main findings of PERFECT, a sub-study of the EUROPA trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: ACE inhibition and endothelial function: Main findings of PERFECT, a sub-study of the EUROPA trial Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
rdfs:seeAlso	http://dx.doi.org/10.1007/s10557-007-6041-3
Description	ACE inhibition results in secondary prevention of coronary artery disease (CAD) through different mechanisms including improvement of endothelial dysfunction. The Perindopril-Function of the Endothelium in Coronary artery disease Trial (PERFECT) evaluated whether long-term administration of perindopril improves endothelial dysfunction. PERFECT is a 3-year double blind randomised placebo controlled trial to determine the effect of perindopril 8 mg once daily on brachial artery endothelial function in patients with stable CAD without clinical heart failure. Endothelial function in response to ischaemia was assessed using ultrasound. Primary endpoint was difference in flow-mediated vasodilatation (FMD) assessed at 36 months. In 20 centers, 333 patients randomly received perindopril or matching placebo. Ischemia-induced FMD was 2.7% (SD 2.6). In the perindopril group FMD went from 2.6% at baseline to 3.3% at 36 months and in the placebo group from 2.8 to 3.0%. Change in FMD after 36 month treatment was 0. ACE inhibition results in secondary prevention of coronary artery disease (CAD) through different mechanisms including improvement of endothelial dysfunction. The Perindopril-Function of the Endothelium in Coronary artery disease Trial (PERFECT) evaluated whether long-term administration of perindopril improves endothelial dysfunction. PERFECT is a 3-year double blind randomised placebo controlled trial to determine the effect of perindopril 8 mg once daily on brachial artery endothelial function in patients with stable CAD without clinical heart failure. Endothelial function in response to ischaemia was assessed using ultrasound. Primary endpoint was difference in flow-mediated vasodilatation (FMD) assessed at 36 months. In 20 centers, 333 patients randomly received perindopril or matching placebo. Ischemia-induced FMD was 2.7% (SD 2.6). In the perindopril group FMD went from 2.6% at baseline to 3.3% at 36 months and in the placebo group from 2.8 to 3.0%. Change in FMD after 36 month treatment was 0. (en)
Title	ACE inhibition and endothelial function: Main findings of PERFECT, a sub-study of the EUROPA trial ACE inhibition and endothelial function: Main findings of PERFECT, a sub-study of the EUROPA trial (en)
skos:prefLabel	ACE inhibition and endothelial function: Main findings of PERFECT, a sub-study of the EUROPA trial ACE inhibition and endothelial function: Main findings of PERFECT, a sub-study of the EUROPA trial (en)
skos:notation	RIV/00216208:11120/07:00003082!RIV12-MSM-11120___
http://linked.open...avai/riv/aktivita	N V
http://linked.open...avai/riv/aktivity	N, V
http://linked.open...iv/cisloPeriodika	4
http://linked.open...vai/riv/dodaniDat	2012
http://linked.open...aciTvurceVysledku	Widimský, P. Špaček, Rudolf
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Univerzita Karlova v Praze / 3. lékařská fakulta
http://linked.open...dnocenehoVysledku	408404
http://linked.open...ai/riv/idVysledku	RIV/00216208:11120/07:00003082
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	ACE inhibition; Atherosclerosis; Brachial reactivity; Cardiovascular disease prevention; Coronary heart disease; Endothelial function (en)
http://linked.open.../riv/klicoveSlovo	Endothelial function Atherosclerosis ACE inhibition Coronary heart disease Brachial reactivity Cardiovascular disease prevention
http://linked.open...odStatuVydavatele	NL - Nizozemsko
http://linked.open...ontrolniKodProRIV	[694FB5E07C8D]
http://linked.open...i/riv/nazevZdroje	Cardiovascular Drugs and Therapy
http://linked.open...in/vavai/riv/obor	FA
http://linked.open...ichTvurcuVysledku	2 (xsd:int)
http://linked.open...cetTvurcuVysledku	45 (xsd:int)
http://linked.open...UplatneniVysledku	2007
http://linked.open...v/svazekPeriodika	21
http://linked.open...iv/tvurceVysledku	Widimský, Petr Špaček, Rudolf Bots, M. L.
http://linked.open...ain/vavai/riv/wos	000249402800007
issn	0920-3206
number of pages	11 (xsd:int)
http://bibframe.org/vocab/doi	10.1007/s10557-007-6041-3
http://localhost/t...ganizacniJednotka	11120
is http://linked.open...avai/riv/vysledek of	ACE inhibition and endothelial function: Main findings of PERFECT, a sub-study of the EUROPA trial

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 41 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software